Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis

about

Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis

Item

http://www.wikidata.org/entity/Q58768916

description

scientific article published on 03 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Adverse clinical outcomes asso ...... matic review and meta-analysis

@en

Adverse clinical outcomes asso ...... matic review and meta-analysis

@nl

type

Item

label

Adverse clinical outcomes asso ...... matic review and meta-analysis

@en

Adverse clinical outcomes asso ...... matic review and meta-analysis

@nl

prefLabel

Adverse clinical outcomes asso ...... matic review and meta-analysis

@en

Adverse clinical outcomes asso ...... matic review and meta-analysis

@nl

P1476

Adverse clinical outcomes asso ...... matic review and meta-analysis

@en

P2093

Bi Zhuo

http://www.w3.org/2001/XMLSchema#string

Pei Niu

http://www.w3.org/2001/XMLSchema#string

Shenyu Ouyang

http://www.w3.org/2001/XMLSchema#string

Xiaojun Zhuo

http://www.w3.org/2001/XMLSchema#string

P2860

Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Measuring inconsistency in meta-analyses

Antiplatelet treatment in stable coronary artery disease

The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective.

A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.

Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention

Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy

High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study.

Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti

P2888

s40360-018-0247-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1186/S40360-018-0247-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Mou Xiao

P577

2018-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1106525596

http://www.w3.org/2001/XMLSchema#string

P698

30176938

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

P932

6122215

http://www.w3.org/2001/XMLSchema#string